MAPT and Parkinson disease: Further clinical follow-up, and the approved brain donation program in the PPMI as well as future biomarker approaches, for example, the ratio of α-syn/tau protein,36 neurofilament light chain,37 or others could help to distinguish PD from atypical PD syndromes.